Description of Immunologic, Enzymatic and Metabolic Biomarkers Associated to the Severity of COVID-19 (SARS-CoV-2) and Its Resolution
Completed
- Conditions
- Covid19
- Registration Number
- NCT04664023
- Lead Sponsor
- Poitiers University Hospital
- Brief Summary
Prospective study to describe the immunological, metabolic and serologic profile in the acute and post acute phases of Coronavirus disease (COVID-19)
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 130
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method T CD8 lymphocytes At Month 12 after the second injection of vaccine against COVID-19 for volunteers Blood concentration of glucosidases
Inflammatory markers At Month 12 after the second injection of vaccine against COVID-19 for volunteers Blood concentration of glucosidases
Neutralizing antibodies At Month 12 after the second injection of vaccine against COVID-19 for volunteers Blood concentration of glucosidases
Metabolic markers At Month 12 after the second injection of vaccine against COVID-19 for volunteers Blood concentration of glucosidases
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
How do cytokine profiles and metabolic biomarkers correlate with acute vs. post-acute severity in NCT04664023?
What role do enzymatic markers like LDH or CRP play in predicting outcomes compared to standard-of-care treatments for severe SARS-CoV-2?
Which immunologic biomarkers identified in NCT04664023 predict long-COVID resolution after 12 months post-infection?
How do immune checkpoint inhibitors or metabolic modulators manage cytokine storm risks observed in this trial's longitudinal data?
What insights from NCT04664023's vaccine-induced immune responses inform combination therapies with antivirals or monoclonal antibodies?
Trial Locations
- Locations (1)
C.H.U.de Poitiers
🇫🇷Poitiers, France
C.H.U.de Poitiers🇫🇷Poitiers, France